---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-080311"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2026-07-02T20:05:35+00:00"
generated_at: "2026-07-02T20:07:18.863250+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TransCode adjourns annual meeting to July 20 pending Nasdaq approval of stock conversion

## Summary
- Annual meeting adjourned from July 2 to July 20, 2026, at 9:30 a.m. ET.
- All proposals have received necessary stockholder support, but Nasdaq has not yet approved initial listing application for conversion of Series A and B preferred stock to common.
- Company believes it meets Nasdaq Capital Market initial listing criteria, but no assurance of outcome or timing.
- Record date remains May 28, 2026; stockholders who haven't voted can vote via proxy or at reconvened meeting.
- No changes to proposals; company continues soliciting votes.

## SEC filing metadata
- accession: 0001104659-26-080311
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2026-07-02T20:05:35+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465926080311/0001104659-26-080311-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465926080311/tm2619681d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-080311
- JSON: https://secwatch.observer/filing/0001104659-26-080311.json
- Plain text: https://secwatch.observer/filing/0001104659-26-080311.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.